에토미데이트

용도

• As an induction agent
• As an induction agent
• As an induction agent
• As an induction agent in the cardiovascular unstable patient
• As an induction agent in the cardiovascular unstable patient (Rabbits)
• As an induction agent
• As an induction agent
• As an induction agent

투여 방법

가능한 부작용

• Pain at intravenous injection site
• Myoclonus (skeletal muscle movements)
• Vomiting and post-operative retching
• Eye movements
• Hemolysis (due to propylene glycol carrier)
• Brief hypoventilation and decreased arterial blood pressure
• Apnea, laryngospasm, or hiccups (reported in humans)

주의사항 및 금기

• Known hypersensitivity to etomidate
• Maintenance of anesthesia (due to cumulative adrenal suppression)
• Use as a sole agent for painful procedures (lacks analgesia)
• > **Adrenocortical Suppression:** Etomidate inhibits cortisol production. It should only be used for induction, not maintenance. Use with extreme caution in patients with impaired adrenocortical function. Exogenous glucocorticoids (e.g., dexamethasone) should be considered in severely compromised animals. * **Hepatic/Renal Impairment:** Elimination half-lives may be significantly increased. The propylene glycol carrier may be problematic in patients with liver dysfunction. * **Hemolysis & Pain:** Injecting into a running IV line is recommended to decrease pain on injection and potentially reduce hemolysis caused by the propylene glycol vehicle. * **Premedication:** Administering a benzodiazepine (diazepam, midazolam) or opiate prior to etomidate can minimize myoclonus, vomiting, and potential seizure-like activity.

약물 상호작용

• CNS/Respiratory Depressants (e.g., barbiturates, opiates, anesthetics): Additive pharmacological effects; can increase CNS or respiratory depression.
• Verapamil: Associated with potentiating the anesthetic and respiratory depressant effects of etomidate.

자주 묻는 질문